 Since GBM is one of the most vascularised cancers, antiangiogenic agents have been tested and used firstly in recurrent GBM. Among them, Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor VEGF, has shown high response rate between 19 and 62 in several Phase 2 and multiple retrospective studies, alone or in combination with chemotherapy Chamberlain 2011. Two randomized phase III trials, AVAGLIO and RTOG 0825, investigating the efficacy of Bevacizumab added or not to the Stupp protocol in patients with newly diagnosed GBM, have been presented at the annual meeting of the American Society of Clinical Oncology ASCO 2013. While both studies exhibited a significant progression-free survival PFS improvement RTOG 0825:10.7 vs. 7.3m, p0.007; AVAGLIO: 10.6 vs. 6.2m, p0.0001, there was no gain in overall survival. 